Genital warts among 18- to 59-year-olds in the United States, National Health and Nutrition Examination Survey, 1999-2004

Sexually Transmitted Diseases

Volumn 35, Issue 4, 2008, Pages 357-360

  Dinh, Thu Ha ^a,b   Sternberg, Maya ^a   Dunne, Eileen F ^a   Markowitz, Lauri E ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COCAINE; STREET DRUG;

ADULT; AGE DISTRIBUTION; ARTICLE; CONDYLOMA ACUMINATUM; CONFIDENCE INTERVAL; DATA ANALYSIS; DEMOGRAPHY; DISEASE ASSOCIATION; DRUG USE; ETHNICITY; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; RACE DIFFERENCE; SEX RATIO; SEXUAL BEHAVIOR; SEXUALITY; UNITED STATES; WART VIRUS;

ADOLESCENT; ADULT; CONDYLOMATA ACUMINATA; DEMOGRAPHY; FEMALE; HEALTH SURVEYS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NUTRITION SURVEYS; PREVALENCE; SEXUAL BEHAVIOR; SEXUAL PARTNERS; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

EID: 41149136285     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/OLQ.0b013e3181632d61     Document Type: Article

References (15)

1. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997; 102:3-8.
2. Ireland JA, Reid M, Powell R, et al. The role of illness perceptions: Psychological distress and treatment-seeking delay in patients with genital warts. Int J STD AIDS 2005; 16:667-670.
3. Insinga RP, Dasbach EJ, Elbasha EH. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: Analytic framework and review of the literature. Pharmacoeconomics 2005; 23:1107-1122.
4. Brown DR, Schroeder JM, Bryan JT, et al. Detection of multiple human papillomavirus types in Condylomata acuminata lesions from otherwise healthy and immunosuppressed patients. J Clin Microbiol 1999; 37:3316-3322.
5. Lacey CJN, Lowndes CM, Shah KV. Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006; 24:S35-S41.
6. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: A randomized double-blind placebo-controlled multi centre phase II efficacy trial. Lancet Oncol 2005; 6:271-278.
7. Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006; 95:1459-1466.
8. Markowitz LE, Dunne EF, Saraiya M, et al; Centers for Disease Control and Prevention. Recommendations and Reports. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2007; 56:1-24.
9. Botman S, Moore T, Parsons VL. Design and estimation for the National Health Interview Survey, 1995-2004. National Center for Health Statistics. Vital Health Stat 2000; 2:1-31.
10. Korn E, Graubard B. Analysis of Health Surveys. New York: Wiley, 1999.
11. Casella G, Berger R. Statistical Inference. Pacific Grove, CA: Wadsworth & Brooks/Col, 1990.
12. Insinga RP, Dasbach EJ, Myers ER. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis 2003; 36:1397-1403.
13. Koshiol JE, Laurent SA, Pimenta JM. Rate and predictors of new genital warts claims and genital warts-related healthcare utilization among privately insured patients in the United States. Sex Transm Dis 2004; 31:748-752.
14. Hariri S, Dunne EF, Sternberg MR, et al. Seroepidemiology of HPV-11 in the United States: Results from the Third National Health and Nutrition Examination Survey, 1991-1994. Sex Transm Dis 2008; 35:298-303.
15. Insinga RP, Glass AG, Rush BB. The health care costs of cervical human papillomavirus-related disease. Am J Obstet Gynecol 2004; 191:114-120.